Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) has a very poor prognosis with a median overall survival of four to nine months. Achieving a complete molecular response is most often required to obtain a sustained leukemia-free survival after allogeneic hematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Voruz, Sophie, Blum, Sabine, de Leval, Laurence, Schoumans, Jacqueline, Solly, Françoise, Spertini, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686620/
https://www.ncbi.nlm.nih.gov/pubmed/34930453
http://dx.doi.org/10.1186/s40364-021-00343-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686620/
https://www.ncbi.nlm.nih.gov/pubmed/34930453
http://dx.doi.org/10.1186/s40364-021-00343-3

Ejemplares similares